Citius Expands LYMPHIR Access Across Europe With Uniphar Deal

Cancer-focused biotechnology company Citius Oncology, Inc. has entered an exclusive distribution agreement with international healthcare services group Uniphar to expand patient access to LYMPHIR outside the United States, marking the company’s third international partnership for the therapy.

The agreement covers designated territories across Western and Eastern Europe, where the treatment will be supplied through country-specific managed access programs when permitted by local regulations. Under the arrangement, Uniphar will manage market access and distribution activities, while Citius Oncology will provide finished product supply and operational support.

LYMPHIR is not approved for commercial sale outside the U.S. and will not be formally launched as a marketed drug in the covered regions at this stage. Instead, it will be made available only through regulated access pathways designed to allow physicians to treat patients with limited therapeutic options while regulatory processes continue.

Chief Executive Officer Leonard Mazur said the collaboration reflects a strategy centered on regional partnerships rather than direct commercialization. According to Mazur, working with established healthcare distributors enables the company to expand responsibly while building the foundation for future global growth.

Uniphar leadership emphasized the clinical importance of the therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma affecting the skin. Brian O’Shaughnessy said the partnership aligns with the company’s goal of connecting patients to innovative treatments and supporting clinicians treating difficult-to-manage cancers.

The latest deal follows previous agreements covering Southern Europe, the Balkans, Turkey and the Middle East, demonstrating a phased expansion approach. By partnering with regional distributors that already have regulatory expertise and healthcare infrastructure, the company aims to accelerate access without undertaking immediate full-scale commercial launches in each market.

Industry observers note that managed access programs are increasingly used by biotechnology firms to introduce specialized oncology therapies internationally while gathering real-world clinical experience and pursuing regulatory approvals. Such programs can provide treatment to patients sooner while companies evaluate reimbursement pathways and country-specific requirements.

For Citius Oncology, the Uniphar collaboration represents another step toward establishing a global presence for LYMPHIR and strengthening its oncology portfolio. If regulatory approvals follow, the company could transition from managed access distribution to broader commercialization across Europe, potentially expanding treatment availability for CTCL patients who currently face limited therapeutic choices.